Key opinion leaders: independent experts or drug representatives in disguise?

Affiliations

Ray Moynihan. BMJ. 2008.

. 2008 Jun 21;336(7658):1402-3.

doi: 10.1136/bmj.39575.675787.651.

¹ University of Newcastle, Newcastle, New South Wales, Australia. Ray.moynihan@newcastle.edu.au

Abstract

Ray Moynihan examines the role of the influential experts paid by industry to help “educate” the profession and the public

Competing interests: None declared.

Key opinion leaders: Thus are our medical meetings managed.
Fugh-Berman A. Fugh-Berman A. BMJ. 2008 Jul 15;337(7662):a789. doi: 10.1136/bmj.a789. BMJ. 2008. PMID: 18632708 Free PMC article. No abstract available.
Key opinion leaders: How to spot one.
Spiers AS. Spiers AS. BMJ. 2008 Jul 15;337(7662):a790. doi: 10.1136/bmj.a790. BMJ. 2008. PMID: 18632709 Free PMC article. No abstract available.
Key opinion leaders: Getting them while they're young.
Reynolds CJ, Yates T, Hughes R. Reynolds CJ, et al. BMJ. 2008 Jul 15;337(7662):a792. doi: 10.1136/bmj.a792. BMJ. 2008. PMID: 18632710 Free PMC article. No abstract available.

1. Pharma Marketing Glossary. www.pharma-mkting.com/glossary/keyopinionleader.htm
1. Cutting Edge Information. Thought-leader compensation: establishing fair-market value http://cuttingedgeinfo.com/thoughtleadercompensation/PH106_summary.pdf, summary.
1. Cutting Edge Information. Pharmaceutical opinion leader management. November 2007. www.cuttingedgeinfo.com/pharmaopinionleaders/index.htm#body, summary.
1. Marketwire. Large pharmaceutical companies tend to pay triple what other size companies do for KOL speakers Press release, 19 March, 2008www.marketwire.com/mw/release.do?id=834122
1. Cook J. Practical guide to medical education. Pharmaceutical Marketing 2001;6:14-22.